4
Total investments
0
Early stage
2
Mid stage
0
Late stage
2y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Jul 2024
Personal genomics solution for predictive medicine—Thanks to unique and groundbreaking technology, Predictiv identifies the genetic predispositions of an individual on 22,000+ diseases and simulated reactions to 750+ drugs. Now enabling more accurate preventive actions and treatments.
Board Member
Apr 2024
At Silicon Valley Innovations, we’re on a mission to create exceptional technology in order to help people lead happier, healthier lives. Our passionate team has more than three decades of experience in the medical device industry and we’re committed to improving everyday lives of everyday people.
Experience · 5 entries
All (5)
Investments (4)
Board (4)
2024
Board Member
Jul 2024
Dignify Therapeutics is a neurological drug and medical device development company focused on delivering novel therapies for neurogenic bladder and bowel disorders in spinal cord injured, multiple sclerosis and similar patient populations.
Board Member
Jul 2024
Personal genomics solution for predictive medicine—Thanks to unique and groundbreaking technology, Predictiv identifies the genetic predispositions of an individual on 22,000+ diseases and simulated reactions to 750+ drugs. Now enabling more accurate preventive actions and treatments.
Board Member
Apr 2024
At Silicon Valley Innovations, we’re on a mission to create exceptional technology in order to help people lead happier, healthier lives. Our passionate team has more than three decades of experience in the medical device industry and we’re committed to improving everyday lives of everyday people.
C
Covanos, Inc.
Board Member
Jan 2024
2002
Managing Director
Mar 2002
Founded in 1993, Montreux Equity Partners is a private investment firm focused on making growth capital investments in the leading companies of tomorrow. Our portfolio companies address the most compelling domestic and global trends in health. We are currently investing out of our fifth fund.
We focus on commercial stage companies that possess highly differentiated products, technologies, and services. At the time of investment, a company will typically have $5 to $50 million in revenues. We typically invest $10 to $20 million per company, and our capital fuels product expansion, new market entry, and strategic acquisitions.